

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

Strategies to Augment Ketosis: Optimization of Ketone Delivery(STAK:OK'd)

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

The Ohio State University

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

IRB Approval July 26, 2022

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

IRB# 2022H0160

The Ohio State University Consent to Participate in Research

Study Title: Strategies to Augment Ketosis: Optimization of Ketone delivery (STAK OK'd)

Principal Investigator: Jeff Volek PhD, R.D.

Sponsor: Department of Defense (DOD)
BHB Therapeutics/ Juvenescence
Abbott Laboratories

- **This is a consent form for research participation.** It contains important information about this study and what to expect if you decide to participate. Please consider the information carefully. Feel free to discuss the study with your friends and family and to ask questions before making your decision whether or not to participate.
- **Your participation is voluntary.** You may refuse to participate in this study. If you decide to take part in the study, you may leave the study at any time. No matter what decision you make, there will be no penalty to you and you will not lose any of your usual benefits. Your decision will not affect your future relationship with The Ohio State University. If you are a student or employee at Ohio State, your decision will not affect your grades or employment status.
- **You may or may not benefit as a result of participating in this study.** Also, as explained below, your participation may result in unintended or harmful effects for you that may be minor or may be serious depending on the nature of the research.
- **You will be provided with any new information that develops during the study that may affect your decision whether or not to continue to participate.** If you decide to participate, you will be asked to sign this form and will receive a copy of the form. You are being asked to consider participating in this study for the reasons explained below.

Key Information About This Study

The following is a short summary to help you decide whether or not to be a part of this study. More detailed information is listed later in this form.

This study is intended to evaluate the effects of different dosing measurements for different ketone products in healthy male adults. After giving consent to this study you will schedule 9 testing sessions about 3 days apart. During these sessions you will come into the Physical Activity and Education Services (PAES) building in the morning, having had no food that day and take a study product. Various tests will be administered after ingestion. You will have blood draws to tell us more about your metabolic response to the product. We will draw 56mL per testing day, which is less than 4 tablespoons of blood (~3.8 tbsp). For the entire study, we will draw 504mL of blood, which is roughly ~2.1 cups over 4 weeks.

67 You will receive finger sticks that tell us your ketone and glucose levels. Your
68 respiratory gas will be assessed using a Parvo Metabolic Cart as you breathe through a
69 face mask and then a handheld breathe analyzer. You will be asked to complete a
70 couple surveys at the beginning and end of each testing session. From the beginning to
71 end of your participation in the study (~4 weeks) you will wear a Continuous Glucose
72 and Ketone Monitor. This will be applied at your first testing session. We expect the
73 full visit experiment to last 4 hours. You will be monitored at all times by research
74 staff.

75

76

77

78 **1. Why is this study being done?**

79 This study is being done to identify the preferred ketone supplement type, the ideal
80 ketone supplement dose, and those effects on your body. With the widespread use of
81 ketogenic diets, the research on ketones (a molecule created when fat is broken down in
82 the body) has grown as well. It is now possible to increase blood levels of ketones by
83 consuming them directly instead of restricting carbohydrates or prolonged fasting. When
84 ketones are consumed, they are quickly absorbed and increase blood levels of ketones,
85 even in those not consuming a very low-carbohydrate diet. Since they are so new, very
86 little work has been done to show how ketone supplements affect blood-based changes,
87 heart based changes and tolerability. These findings will be used to help develop future
88 research protocols and drive product development.

89

90 **2. How many people will take part in this study?**

91 We will recruit up to 15 healthy and normally-active resistance/endurance trained men from
92 the ages of 20-30 yr that represents typical active-duty military personnel

93

94 **3. What will happen if I take part in this study?**

95 This study will be a single center, randomized study of up to 15 apparently healthy males
96 comparing the effect of an oral ketone supplement in various forms and doses.

97 If enrolled, you will be randomly assigned using an online random sequence generator
98 (randomization.com) that will generate a list of random number sequences between 1 – 9
99 that correspond to product/serving code. If you meet all inclusion and none of the
100 exclusion, a staff member will randomize you in the order that you are enrolled. The
101 randomization number will be recorded in your study documentation.




Figure 1. Study Overview

Study Procedures

Study Day	Screening	Test Days 1-9
Visit to Study Center	X	X
Informed consent	X	
Medical intake questionnaire, taste screening, diet assessment, anthropometrics ¹	X	
Randomization ²	X	
Compliance assessment ³		X
Consume study product ⁴		X
IV Cannulation and whole blood collection ⁵		X
Urine collection ⁶		X
Respiratory gas analysis ⁷		X
Heart rate and HRV monitoring ⁸		X
Tolerability assessment ⁹		X
Satiety assessment ¹⁰		X
Continuous Ketone Monitor placement/check ¹¹		X

1. Medical intake questionnaire, taste screening diet assessment questionnaire and anthropometric data will include: Lean Body Mass by DXA, BMI, height and weight.
 2. Your order of study products will be randomized using a computer randomization generator.

113 3. Prior to starting each test day, you will be asked to confirm that you meet pre-test criteria,
114 including: fasted >10h, no alcohol for 24h, no exercise for 24h and consumed the provided pre-test
115 food.
116 4. Study Product will be consumed within +/- 60 minutes of the time established on the first test
117 day. Participants will be provided with a choice of non-caffeinated, non-caloric beverage to remove
118 the bitter taste of the Study Product.
119 5. IV cannula will be inserted at the start of each Test Day, and removed at the end of each Test
120 Day. Blood samples will be collected according to the schedule in Figure 1. Cannula will be flushed
121 with a small volume of saline after each sample to maintain patency. We will draw 56 mL of blood,
122 per testing day, which is less than 4 table spoons.
123 6. Prior to consumption of the Study Product, participants will be asked to completely void your
124 bladder. And hydration status will be determined via urine specific gravity (USG) reporting <1.025.
125 Urine passed after the ingestion of the study product will be collected in a plastic container; you will
126 be asked to void their bladder and collect urine at the end of the test day. The volume produced will
127 be recorded at the end of the study and aliquots will be frozen and stored for future analysis.
128 7. You will breathe into a commercially available handheld breath acetone analyzer according to
129 the schedule in Figure 1. Participants will wear a fitted face mask attached to a metabolic cart for a
130 10-minute period every 60 minutes.
131 8. Participants will wear a Bluetooth heart rate monitor chest strap throughout the test day.
132 9. Participants will complete a Beverage Tolerability Questionnaire prior to Study Product
133 consumption and at the end of the Test Day.
134 10. Participants will complete a 3-item satiety visual analogue scale prior to Study Product
135 consumption and at the end of the Test Day.
136 11. Continuous Ketone Monitor will be applied at the start of Test Day 1. The sensor will be checked
137 by the study team at each test day and will be removed and replaced by a fresh sensor at ~2- week
138 intervals during the study. The sensor will be removed at the end of the final test day.
139

140 Screening Visit: If you meet the initial qualifying criteria you will visit the study center for a screening
141 meeting. You and a member of the research team will meet in a private office to discuss this form.
142 The study will be described in full detail and any questions you have will be answered. If you choose
143 to participate you will be asked to sign the consent form providing written consent to be apart of the
144 study. Even though you have signed the informed consent, you may stop the study at any time.
145

146 If you do consent, you will be provided with questionnaires about your diet and medical history. All
147 collected samples and data will be coded to maintain your privacy. We will give you a small volume of
148 Study Product to screen for tolerance of the bitter tasting Study Products. You will complete a DXA scan
149 to assess body composition.
150
151

152 **4. How long will I be in the study?**

153 The duration of this study is expected to be approximately 4 weeks, which includes
154 consent and screening, and two times per week study testing. Total hours of commitment
155 should be approximately 38 hours. This will include 9 sessions of 4 hours (~36 hours)
156 and a 2-hour consent/screening/baseline testing session.
157

158 **5. Can I stop being in the study?**

159 You may leave the study at any time. If you decide to stop participating in the study,
160 there will be no penalty to you, and you will not lose any benefits to which you are
161
162

163 otherwise entitled. Your decision will not affect your future relationship with The Ohio
164 State University.

165

166 **6. What risks, side effects or discomforts can I expect from being in the study?**

167 **Ketone Supplements.**

168 Drinking the supplement beverage could cause some people to have discomfort such as
169 stomach cramps, nausea, vomiting or diarrhea. Additionally, this study is designed to
170 assess palatability and tolerability of the supplement therefore it is possible that you may
171 not like the taste of the product in one or all of the provided forms.

172

173 **Continuous Ketone/Glucose Monitor**

174 The patch application may cause a slight immediate discomfort at the specific stick site.
175 Under normal conditions, there are minimal risks to you when performing application that
176 include: bruising; light-headedness or dizziness due to fear of needles; and infection.

177

178 **Blood Draws**

179 Blood draws will be done via an in-dwelling IV catheter. The insertion of this catheter
180 may cause discomfort at the skin puncture site and a small bruise may develop that may
181 persist for several weeks. Risks of IV cannulation include but not limited to: a)
182 Occasionally: discomfort, bruising and pain at the site of injection. b) Rarely:
183 inflammation of the vein used for injection, phlebitis (vein irritation), metabolic
184 disturbances, and injury. c) Extremely Rare: Severe allergic reaction, anaphylaxis
185 (inability to breathe), infection, cardiac arrest, and death. Venous access for blood draws
186 will be rotated at each testing day to let your veins recover appropriately. We will draw
187 56mL per testing day, which is less than 4 tablespoons of blood (~3.8 tbsp). For the entire
188 study, we will draw 504mL of blood, which is roughly ~2.1 cups over 4 weeks. Risks are
189 minimized by using sterile disposable needles and gauze and the practice of aseptic
190 (sterile) techniques during the blood draw.

191

192 **Body Composition-DXA**

193 You will be exposed to a very small amount of radiation by the scanner used to measure
194 your body composition. Exposure to any amount of X-ray radiation, no matter how low,
195 may cause abnormal changes in cells. DXA includes exposure to radiation similar to a flight
196 from New York to Los Angeles or 125 times less than the radiation associated with a
197 standard chest x-ray; any exposure to radiation may elevate cancer risk. The total amount
198 of radiation that you will receive in this study is about 0.39 mSv or 39 mrem, and is
199 approximately equivalent to a uniform whole body exposure of 47 days of exposure to
200 natural background radiation. This use involves minimal risk and is necessary to obtain the
201 research information desired.

202

203

204 **7. What benefits can I expect from being in the study?**

205

206 You will receive body composition analysis from your DXA scan. Other than that, there
207 are no potential benefits to being in the study. If there are unusual findings, we will
208 consult with a physician.

209

210 **8. What other choices do I have if I do not take part in the study?**

211

212 You may choose not to participate without penalty or loss of benefits to which you are
213 otherwise entitled.

214

215 **9. Will my study-related information be kept confidential?**

216

217 Efforts will be made to keep your study-related information confidential. However, there
218 may be circumstances where this information must be released. For example, personal
219 information regarding your participation in this study may be disclosed if required by state
220 law.

221

222 Also, your records may be reviewed by the following groups (as applicable to the
223 research):

224

- 225 • Office for Human Research Protections or other federal, state, or international
regulatory agencies;
- 226 • U.S. Food and Drug Administration;
- 227 • The Ohio State University Institutional Review Board or Office of Responsible
Research Practices;
- 228 • The sponsor supporting the study, their agents or study monitors; and
- 229 • Your insurance company (if charges are billed to insurance).

230

231 If this study is related to your medical care, your study-related information may be placed
232 in your permanent hospital, clinic, or physician's office records. Authorized Ohio State
233 University staff not involved in the study may be aware that you are participating in a
234 research study and have access to your information.

235

236

237 **10. Will my de-identified information and bio-specimens be used or shared for
238 future research?**

239

240 Yes, it/they may be used or shared with other researchers without your additional
241 informed consent.

242

243 **11. What are the costs of taking part in this study?**

244 There is no cost to you or your insurance company for participating in this research
245 study. There is no cost to you for the food you will be provided.

246

247 **12. Will I be paid for taking part in this study?**

249 By law, payments to subjects are considered taxable income. \$30 will be received for
250 completing each day of testing (9 days), plus enrollment + familiarization day (1 day). If
251 all testing days are completed this will equal to \$300.00. Payments will be provided in the
252 form of check at the completion of the study or upon study withdrawal, if occurring prior
253 to final testing day.

254

255 **13. What happens if I am injured because I took part in this study?**

256

257 If you suffer an injury from participating in this study, you should notify the researcher or
258 study doctor immediately, who will determine if you should obtain medical treatment at
259 The Ohio State University Wexner Medical Center.

260 The cost for this treatment will be billed to you or your medical or hospital insurance. The
261 Ohio State University has no funds set aside for the payment of health care expenses for
262 this study.

263

264 **14. What are my rights if I take part in this study?**

265

266 If you choose to participate in the study, you may discontinue participation at any time
267 without penalty or loss of benefits. By signing this form, you do not give up any personal
268 legal rights you may have as a participant in this study.

269

270 You will be provided with any new information that develops during the course of the
271 research that may affect your decision whether or not to continue participation in the
272 study.

273

274 You may refuse to participate in this study without penalty or loss of benefits to which
275 you are otherwise entitled.

276

277 An Institutional Review Board responsible for human subjects research at The Ohio State
278 University reviewed this research project and found it to be acceptable, according to
279 applicable state and federal regulations and University policies designed to protect the
280 rights and welfare of research participants.

281

282 **15. Who can answer my questions about the study?**

283

284

285 For questions, concerns, or complaints about the study you may contact Drs Madison
286 Kackley, 614-247-9650 or Brianna Stubbs, 415-209-2000

287

288 For questions about your rights as a participant in this study or to discuss other study-
289 related concerns or complaints with someone who is not part of the research team, you
290 may contact the Office of Responsible Research Practices at 1-800-678-6251.

291

292 If you are injured as a result of participating in this study or for questions about a study-
293 related injury, you may contact **Dr. Jeff Volek 614-688-1701**.

295 **Signing the consent form**

296
297 I have read (or someone has read to me) this form and I am aware that I am being asked to
298 participate in a research study. I have had the opportunity to ask questions and have had them
299 answered to my satisfaction. I voluntarily agree to participate in this study.

300
301 I am not giving up any legal rights by signing this form. I will be given a copy of this form.
302

Printed name of participant	Signature of participant	AM/PM
	Date and time	
Printed name of person authorized to consent for participant (when applicable)	Signature of person authorized to consent for participant (when applicable)	AM/PM
Relationship to the participant	Date and time	

303 **Investigator/Research Staff**

304
305
306 I have explained the research to the participant or his/her representative before requesting the
307 signature(s) above. There are no blanks in this document. A copy of this form has been given
308 to the participant or his/her representative.
309
310
311

Printed name of person obtaining consent	Signature of person obtaining consent	AM/PM
	Date and time	

312 **Witness(es) - May be left blank if not required by the IRB**

Printed name of witness	Signature of witness	AM/PM
	Date and time	
Printed name of witness	Signature of witness	AM/PM
	Date and time	